Gilbert A. Fuller Sells 675 Shares of USANA Health Sciences, Inc. (NYSE:USNA) Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director Gilbert A. Fuller sold 675 shares of the company’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $37.71, for a total value of $25,454.25. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Gilbert A. Fuller also recently made the following trade(s):

• On Wednesday, August 7th, Gilbert A. Fuller sold 674 shares of USANA Health Sciences stock. The stock was sold at an average price of $39.69, for a total value of $26,751.06.

USANA Health Sciences Stock Up 0.4 %

NYSE:USNA opened at $40.50 on Friday. The stock has a market capitalization of $771.93 million, a price-to-earnings ratio of 14.31, a PEG ratio of 1.37 and a beta of 0.89. USANA Health Sciences, Inc. has a 52 week low of $34.15 and a 52 week high of $54.81. The firm has a 50 day moving average of $37.52 and a 200 day moving average of $42.06.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.07. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The company had revenue of $200.22 million for the quarter, compared to analyst estimates of $208.45 million. During the same period in the prior year, the company posted $0.59 EPS. As a group, analysts expect that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

Hedge Funds Weigh In On USANA Health Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its position in USANA Health Sciences by 18.1% in the first quarter. BNP Paribas Financial Markets now owns 38,820 shares of the company’s stock valued at $1,883,000 after buying an additional 5,952 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its holdings in shares of USANA Health Sciences by 22.7% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 8,430 shares of the company’s stock valued at $409,000 after acquiring an additional 1,560 shares during the last quarter. BOKF NA increased its stake in shares of USANA Health Sciences by 274.5% in the first quarter. BOKF NA now owns 2,771 shares of the company’s stock worth $133,000 after acquiring an additional 2,031 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of USANA Health Sciences by 9.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company’s stock worth $284,000 after purchasing an additional 494 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its position in USANA Health Sciences by 2.6% during the first quarter. Jacobs Levy Equity Management Inc. now owns 111,492 shares of the company’s stock valued at $5,407,000 after purchasing an additional 2,820 shares during the period. Hedge funds and other institutional investors own 54.25% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on USNA shares. DA Davidson reduced their target price on shares of USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 23rd. StockNews.com downgraded USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 24th.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.